Meet PRISMAX

Experience the next generation in CRRT

WHAT IF you could...

Accuracy

Improve treatment ACCURACY and system PERFORMANCE?

Reduce Time icon

Increase workflow EFFICIENCY with less device interactions?

Simplify delivery icon

SIMPLIFY setup and delivery of CRRT?

You Asked. We Listened.

We asked more than 650 ICU healthcare professionals from over 50 ICUs around the world what it would take to solve their greatest challenges in acute care. The PRISMAX system was designed to help meet these needs, building upon Baxter's PRISMAFLEX technology and 20+ years experience in advancing critical care delivery.

 

Take the Virtual Demo.

Select a feature to learn more about the PRISMAX System.

THERMAX Blood Warmer enables precise control of blood return temperature between 35°C and 38°C. Available on the PRISMAX System.

Did you know that hypothermia occurs in 40-50% of CRRT patients even with warming fluids?1,2

Easily managed through the PRISMAX System interface, the THERMAX Blood Warmer accurately warms returning blood to minimize need for warming blankets.3

THERMAX Blood Warmer enables precise control of blood return temperature between 35°C and 38°C.

† Cooling only through therapy fluids, no active cooling of blood through the warmer

Auto-effluent pump on the PRISMAX System.

Now you have a CHOICE
in effluent disposal with your CRRT treatments

PRISMAX System provides you with accurate effluent management options: disposal down a drain or captured in an effluent bag.

The PRISMAFLEX and PRISMAX Systems are intended for:
Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload.

Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where fluid removal of plasma components is indicated.

Rx Only. For safe and proper use of products mentioned herein refer to the appropriate Instructions for Use or Operator's Manual.


PHOXILLUM and PRISMASOL Renal Replacement Solution Indications and Important Risk Information

Indications and Usage 
PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.


Warnings and Precautions 
Electrolyte and Volume Abnormalities
PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately. PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis.

Blood Glucose Abnormalities
The use of PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.

Please see PHOXILLUM and PRISMASOL Solutions full Prescribing Information.


MARS is indicated for the treatment of drug overdose and poisonings. The only requirement is that the drug or chemical be dialyzable (in unbound form) and bound by charcoal and/or ion exchange resins.

MARS is not indicated for the treatment of chronic liver disease conditions or as a bridge to liver transplant. Safety and efficacy has not been demonstrated for those indications in controlled, randomized clinical trials. The effectiveness of the MARS device in patients that are sedated could not be established in clinical studies and therefore cannot be predicted in sedated patients.